Shenogen Pharma agreed to collaborate with Lee's Pharmaceutical to develop and market in China the combination of Lee's ZKAB001 and Shenogen's icaritin for the treatment of late-stage cancers. Shenogen is conducting a Phase III trial of icaritin in hepatocellular carcinoma patients.
Shenogen signs cancer combo deal with Lee's Pharma
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.